Skip to main content
ENDO 2026 Main banner

Adipose Tissue_Appetite_and Obesity

MON-728 - Patient-reported improvements in appetite control, quality of life, and work-related outcomes following tirzepatide treatment for obesity or overweight in the US: Results from 3-month PERCEPTIONS survey

Monday, June 15, 2026
9:00 AM - 2:00 PM CT
Disclosure(s):
Theresa Hunter Gibble, PhD, MPH, MS: No relevant disclosure to display


Objective:
This study aimed to evaluate changes in patient-reported outcomes (PROs) among individuals during their first 3-months of tirzepatide treatment for obesity or overweight.

Methods:
This study presents data from the first 3 months of tirzepatide treatment as part of an ongoing US longitudinal real-world survey (PERCEPTIONS) consisting of PRO measures to assess perceptions and experiences, conducted June 2025-February 2026. Obesity medication-eligible (BMI ≥30 kg/m2, or 27-29.9 kg/m2 with ≥1 obesity-related complication) full-time employees without type 2 diabetes initiating tirzepatide were enrolled. Changes in PRO measure scores were assessed between first tirzepatide dose and +3-months using the Work Productivity and Activity Impairment Questionnaire (WPAI), Impact of Weight on Quality of life-Lite Clinical Trials (IWQOL-Lite-CT), PROMIS sleep-related impairment short form (PROMIS SRI), Modified Weight-Bias Internalization Score (WBIS-M), and the Eating Behaviour and Appetite Questionnaire (EBAQ). Scores were calculated per instrument specific scoring guidelines.

Results:
A total of 461 individuals (mean age 46.0 years, female 77.2%; White 69.6%; mean BMI 38.5 kg/m2) completed both baseline and 3-month assessments and were persistent on tirzepatide. Persistence was defined as remaining on therapy at 3-month follow-up. Improvements from baseline to 3 months were observed across PRO measure scores. WPAI scores demonstrated reductions in absenteeism (mean change, -1.24%; p=0.01) and presenteeism (-4.12%; p< 0.001), and improvements in overall work and activity impairment (-4.31 and -8.92, respectively; p< 0.001). IWQOL-Lite CT scores demonstrated improvements in physical function (+9.25; p< 0.001) and psychosocial scores (+8.86; p< 0.001). PROMIS SRI scores decreased, indicating improved sleep quality (-2.70; p< 0.001), and WBIS-M scores decreased, suggesting decreased weight bias (-0.38; p< 0.001). EBAQ results indicated improved appetite control (+4.28; p< 0.001) and eating behaviors (+2.9; p< 0.001).

Conclusion:
Among individuals who were persistent on tirzepatide for 3 months, improvements were observed in work productivity, psychosocial and physical functioning, sleep, appetite control, eating behaviors, and weight-bias internalization. These findings suggest tirzepatide is associated with broad quality of life benefits in the real-world setting.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*